KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis
Highlights
- Pembrolizumab added to enzalutamide and ADT did not improve radiographic progression-free or overall survival in mHSPC patients.
- Pembrolizumab combination led to higher rates of grade ≥3 and serious adverse events compared to placebo.
- Rash was notably more common with pembrolizumab addition.
- KEYNOTE-991 was stopped early for futility, impacting future immunotherapy strategies for mHSPC.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.